Sama Therapeutics develops an AI-powered precision neuropsychiatry platform called iMAGiNE™ that delivers personalized assessments of brain health. This software as a medical device analyzes complex patient data using generative AI and computational neuroscience to accelerate safer therapeutic development. The platform supports pharmaceutical R&D by de-risking clinical trials and assists providers in delivering more effective, objective mental health and neurological care.
Funding
Funding not disclosed
MVFounders
Product
Problem
Psychiatric and neurological disorders are complex, making it difficult to predict individual treatment responses. Current methods rely on a trial-and-error approach, leading to delays in effective treatment and potentially prolonging patient suffering. Traditional diagnostic methods often lack the precision needed for personalized treatment planning.
Solution
Sama Therapeutics offers iMAGiNE™, an AI-powered biomarker platform that integrates computational neuroscience and machine learning to predict treatment responses for psychiatric and neurological disorders. The platform analyzes data from psychometrics, EEG/ECG, and VR assessments to provide personalized insights into brain health. By identifying clinically-actionable biomarkers, iMAGiNE™ aims to de-risk clinical and preclinical R&D, accelerate clinical trials, and enable providers to deliver more effective treatments. The platform generates prospective insights on dosing, efficacy, adverse events, and placebo effects, helping to eliminate the trial-and-error approach to mental health and neurological care.
Target Audience
The primary target audience includes pharmaceutical companies, clinical research organizations, and healthcare providers specializing in mental health and neurological disorders, as well as individuals interested in personal brain health optimization.
Features
- AI/ML models trained on cross-validated datasets to predict treatment response
- Analysis of psychometric data, EEG/ECG readings, and VR-based assessments
- Identification of transdiagnostic biomarkers for cognitive, affective, interoceptive, and substance use disorders
- Integration of generative AI with computational neuroscience for deep phenotyping and causal inference
- Support for precision clinical trials, digital twins, and preclinical translation
- Clinic integrations for improved understanding of patient conditions and progress measurement
- Reporting and insights for biohackers and individuals interested in optimizing brain health